To our knowledge, monoclonal antibodies immunotherapy targeted human IFN-γ-1b [111] and IL-6R [112] in schizophrenia are ongoing, particularly IL-6R monoclonal antibody has significant improvements in cognition. Here, IL6R is linked to schizophrenia.